Trade fight between US and China could ruin bid for vaccine patent waiver
But pharma groups may welcome the WTO fight, which say an IP waiver is unnecessary as the supply of Covid-19 vaccines outstrips demand
A brewing trade fight between the US and China may unravel a nearly two-year effort to ease intellectual-property rules for producing Covid-19 vaccines and cast further doubt on the World Trade Organisation’s (WTO) reputation as a negotiating forum.
US President Joe Biden’s top trade official in Geneva said any WTO agreement related to Covid-19 vaccines must explicitly exclude China from being able to benefit from the deal.
“The second-largest economy in the world, which has Covid-19 vaccines and mRNA technology, doesn’t need the waiver,” deputy US trade representative Maria Pagan told Bloomberg News in an interview. “What we want is clarity.”
Pagan also said the US would not accept Beijing’s offer to voluntarily opt out of an agreement in return for dropping a provision that currently excludes China. “No, we want it to be clear,” Pagan said.
The Biden administration’s refusal to accept China’s offer could sink a deal that many view as a critical test of the WTO’s relevance after the beleaguered organisation failed to advance any multilateral agreements for the better part of the past decade. Founded in 1995 to encourage lower trade barriers and enforce global rules, the institution has struggled to lean against protectionism that’s taken root in longtime globalisation advocates like the US and UK.
At the same time, the latest WTO impasse may be welcomed by pharmaceutical groups that argue an IP waiver is unnecessary at a time when the supply of Covid-19 vaccines has outstripped demand.
WTO members are entering a make-or-break period to approve an agreement at their ministerial meeting scheduled for June 12-15. The deal must win unanimous support from all 164 WTO members and any one government can block the adoption of a vaccine IP waiver for any reason.
The talks, which seek to authorise the manufacture of Covid-19 jabs without the consent of patent-rights holders, received a boost earlier in May after a preliminary text was produced by WTO director-general Ngozi Okonjo-Iweala and four WTO members — the US, the EU, SA and India.
China, which was initially excluded from the talks, has objected to a key provision that Beijing said would discourage shipments of doses to poorer nations. The current proposal contains a footnote that excludes China because it is the only developing country that exported more than 10% of global Covid-19 vaccine doses.
WTO members met informally in Geneva on Monday ahead of the June ministerial gathering with a view to finding common ground. During the meeting, a Chinese delegate described the issue as a red line, according to an official who was in attendance.
China’s ambassador to the WTO, Li Chenggang, previously said the country could not accept the “unreasonable and arbitrary” provision and said it would cast “serious doubt on how the long-held spirits of unity and co-operation could be preserved” at the WTO.
Instead, Li urged WTO members to opt out of the agreement and said China will not avail itself of the flexibilities under the current text as long as the vaccine waiver remains available to all developing members.
The WTO disagreement comes amid a broader US-China trade conflict that’s still simmering between the world’s largest economies. It also reflects long-running US concerns that China has not fulfilled its existing international trade obligations at the WTO — particularly with respect to the protection of intellectual property.
The Biden administration has largely retained former US president Donald Trump’s tariffs on Chinese exports, which were imposed after the US found that Beijing’s policies encourage the transfer of US technology and intellectual property to enterprises in China.
Bloomberg. More stories like this are available on bloomberg.com
Would you like to comment on this article or view other readers' comments?
Register (it’s quick and free) or sign in now.
Please read our Comment Policy before commenting.